PubMed 検索結果：valsartan AND (retracted OR withdrawn)で検索した 23 件のうち、日本の論文 12 件の要旨

Search results

1.

RETRACTED ARTICLE
See: Retraction Notice
Circ J. 2012. pii: DN/JST.JSTAGE/circj/CJ-12-0387. Epub 2012 Sep 12.

Effects of valsartan on cardiovascular morbidity and mortality
in high-risk hypertensive patients with new-onset diabetes
mellitus.
Kimura S1, Sawada T, Shiraishi J, Yamada H, Matsubara H; KYOTO HEART Study Group.

Author information
1
Department of Cardiology, Kyoto Second Red Cross Hospital Japan.
shinzo@koto.kpu-m.ac.jp

Retraction in
Retraction. Effects of valsartan on cardiovascular morbidity and mortality in high-risk
hypertensive patients with new-onset diabetes mellitus: sub-analysis of the KYOTO
HEART study. [Circ J. 2013]

Abstract
BACKGROUND:The KYOTO HEART Study demonstrated that Valsartan Add-on treatment was effective
to reduce new-onset diabetes in high-risk hypertensive patients. The purpose of thepresent study was to examine the effects of Valsartan Add-on treatment on cardiovascular(CV) events in patients with or without diabetes.
METHODS AND RESULTS:

A total of 3,031 patients were divided at baseline: Baseline Diabetes (n=807) andBaseline Non-Diabetes (n=2,224). Among the Non-Diabetes patients, 144 developeddiabetes (New-Onset Diabetes) and the remaining patients did not throughout the study(Final Non-Diabetes, n=2,080). Baseline Diabetes showed significantly higher CV event
rates than Baseline Non-Diabetes (10.3% vs. 7.0%, P=0.00400). Valsartan Add-on
treatment significantly reduced CV event rates than Non-angiotensin receptor blocker(ARB) treatment both in Baseline Diabetes (6.7% vs. 13.8%, P=0.00274) and in Baseline
Non-Diabetes (5.0% vs. 8.9%, P=0.00036), respectively. New-Onset Diabetes showed asimilar CV event rate (12.5%) to Baseline Diabetes (10.3%) but the event rate wassignificantly higher than that of Final Non-Diabetes (6.6%, P=0.0065). In the New-Onset
Diabetes, Valsartanadd-on treatment significantly reduced CV event rate than Non-ARB
treatment (5.2% vs. 17.4%, P=0.04601).
CONCLUSIONS:

CV event risk in New-Onset Diabetes was relatively equivalent to Baseline
Diabetes. Valsartan Add-on treatment was effective for the reduction of CV events not onlyin Baseline Diabetes but also in New-Onset Diabetes.
PMID:22987054Free full text

2.
Int J Cardiol. 2012 Jul 12. pii: S0167-5273(12)00894-7. doi: 10.1016/j.ijcard.2012.06.103. [Epub ahead of print]

WITHDRAWN: Cardio-cerebrovascular protective effectsof valsartan in high-risk hypertensive patients withoverweight/obesity: A post-hoc analysis of the KYOTO HEART
Study.
Irie H1, Shiraishi J, Sawada T, Koide M, Yamada H, Matsubara H; for the KYOTO HEART Study Group.

Author information
1
Department of Cardiology, Kyoto First Red Cross Hospital, Honmachi,
Higashiyama-ku, Kyoto 605-0981, Japan.

Abstract
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher
apologizes for any inconvenience this may cause. The full Elsevier Policy on Article
Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
PMID:22795716

3.
Int J Cardiol. 2012 Feb 13. pii: S0167-5273(12)00090-3. doi: 10.1016/j.ijcard.2012.01.072. [Epub ahead of print]

WITHDRAWN: Enhanced cardio-renal protective effectsof valsartan in high-risk hypertensive patients with chronic
kidney disease: A sub-analysis of KYOTO HEART Study.
Amano K1, Shiraishi J, Sawada T, Koide M, Yamada H, Matsubara H.

Author information
1
Department of Cardiovascular Medicine, Kyoto Prefectural University School of
Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.

Abstract
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher
apologizes for any inconvenience this may cause. The full Elsevier Policy on Article
Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
PMID:22336256

4.

RETRACTED ARTICLE
See: Retraction NoticeHypertension. 2012 Mar;59(3):580-6. doi: 10.1161/HYPERTENSIONAHA.111.184226. Epub 2012 Jan 9.

Comparison between valsartan and amlodipine regarding
cardiovascular morbidity and mortality in hypertensive patientswith glucose intolerance: NAGOYA HEART Study.
Muramatsu T1, Matsushita K, Yamashita K, Kondo T, Maeda K, Shintani S, Ichimiya S, Ohno M, Sone
T, Ikeda N, Watarai M, Murohara T; NAGOYA HEART Study Investigators.

Collaborators (213)
Author information
1
Department of Cardiology, Nagoya University Graduate School of Medicine, 65
Tsurumai, Showa-ku, Nagoya, 466-8550, Japan.

Erratum inCorrection. [Hypertension. 2015]

Retraction in
Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity andMortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART
Study. [Hypertension. 2018]

Abstract
It has not been fully examined whether angiotensin II receptor blocker is superior to calcium
channel blocker to reduce cardiovascular events in hypertensive patients with glucose
intolerance. A prospective, open-labeled, randomized, controlled trial was conducted forJapanese hypertensive patients with type 2 diabetes mellitus or impaired glucose
tolerance. A total of 1150 patients (women: 34%; mean age: 63 years; diabetes mellitus:82%) were randomly assigned to receive either valsartan- or amlodipine-based
antihypertensive treatment. Primary outcome was a composite of acute myocardial
infarction, stroke, coronary revascularization, admission attributed to heart failure, or
sudden cardiac death. Blood pressure was 145/82 and 144/81 mm Hg, and glycosylated
hemoglobin was 7.0% and 6.9% at baseline in the valsartan group and the amlodipine
group, respectively. Both of them were equally controlled between the 2 groups during thestudy. The median follow-up period was 3.2 years, and primary outcome had occurred in
54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio: 0.97 [95%
CI: 0.66-1.40]; P=0.85). Patients in the valsartan group had a significantly lower incidenceof heart failure than in the amlodipine group (hazard ratio: 0.20 [95% CI: 0.06-0.69];
P=0.01). Other components and all-cause mortality were not significantly different between
the 2 groups. Composite cardiovascular outcomes were comparable between
the valsartan- and amlodipine-based treatments in Japanese hypertensive patients withglucose intolerance. Admission because of heart failure was significantly less inthe valsartan group.
TRIAL REGISTRATION:

ClinicalTrials.gov NCT00129233.

Comment inConcerns for the heart failure reduction in the NAGOYA HEART Study based on metaregression from the evidence. [Hypertension. 2013]

PMID:22232134

5.

RETRACTED ARTICLE
See: Retraction Notice
J Hum Hypertens. 2012 Nov;26(11):656-63. doi: 10.1038/jhh.2011.91. Epub 2011 Oct 13.

Effects of valsartan and amlodipine on home blood pressure
and cardiovascular events in Japanese hypertensive patients: a
subanalysis of the VART.
Takano H1, Hasegawa H, Narumi H, Shindo S, Mizuma H, Kuwabara Y, Kobayashi Y, Komuro I; VART
investigators.

Collaborators (15)Author information
1
Department of Cardiovascular Science and Medicine, Chiba University Graduate
School of Medicine, Chiba, Japan. htakano-cib@umin.ac.jp

Erratum in
J Hum Hypertens. 2013 Sep;27(9):580.

Retraction in
Retraction: Effects of valsartan and amlodipine on home blood pressure and cardiovascular
events in Japanese hypertensive patients: a subanalysis of the VART. [J Hum Hypertens.
2015]

Abstract
The Valsartan Amlodipine Randomized Trial (VART) was performed to compare thebeneficial effects of valsartan and amlodipine on cardiovascular events in Japanese
hypertensive patients. In this subanalysis of the VART, we assessed the relationshipbetween home blood pressure (HBP) levels and cardiovascular events in the enrolled
patients. We enrolled 1021 patients with mild-to-moderate hypertension in the VART. The
participants were allocated randomly to either the valsartan group or the amlodipine group.
The primary end point was a composite of all-cause death, sudden death, cerebrovascular
events, cardiac events, vascular events and renal events. A total of 621 patients(valsartan group: 305 and amlodipine group: 316) completed the measurements of HBP(morning and evening) throughout the trial. Both the agents evenly and significantly
lowered morning HBP and evening HBP throughout the trial. There was no significant
difference in the primary end point between the two groups. However, we observed
significant decreases in the left ventricular mass index and urinary albumin to creatinine
ratio in the valsartan group but not in the amlodipine group. There were no significant
differences in HBP levels and the main outcome of the cardiovascular events between
the valsartan and amlodipine groups. However, in the valsartan group, significant
improvements in left ventricular hypertrophy and microalbuminuria were observed.
PMID:21993491

6.

RETRACTED ARTICLE
See: Retraction Notice
Circ J. 2011;75(4):806-14. Epub 2011 Mar 19.

Enhanced cardiovascular protective effects of valsartan in
high-risk hypertensive patients with left ventricular
hypertrophy--sub-analysis of the KYOTO HEART study.
Shiraishi J1, Sawada T, Kimura S, Yamada H, Matsubara H; KYOTO HEART Study Group.

Author information
1
Department of Cardiology, Kyoto First Red Cross Hospital, Kyoto 605-0981, Japan.
risa11221998@yahoo.co.jp

Retraction inRetraction. Enhanced cardiovascular protective effects of valsartan in high-risk
hypertensive patients with left ventricular hypertrophy: sub-analysis of the KYOTO HEART
study. [Circ J. 2013]

Abstract
BACKGROUND:

The objective of the present study was to examine whether baseline
electrocardiographically diagnosed left ventricular hypertrophy (ECG-LVH) influenced theangiotensin II receptor blocker (ARB) valsartan add-on effects on the cardiocerebrovascular morbidity and mortality in the high-risk hypertensive patients who
participated in the KYOTO HEART Study.
METHODS AND RESULTS:

The primary endpoint was the same as in the main study: a composite of definedcardiovascular and cerebrovascular events. The median follow-up period was 3.27 years.
The study group was divided into 2 groups according to the presence of ECG-LVH: with
LVH, n=803; without LVH, n=2,228. The primary endpoint events occurred more frequently
in patients with LVH than in patients without LVH (9.3% vs. 7.3%; hazard ratio [HR], 1.33;
95% confidence interval [CI]: 1.01-1.75). Valsartan add-on significantly decreased theoccurrence of primary endpoint events in both LVH-positive patients (5.8% vs. 12.9%; HR,
0.45; 95%CI: 0.28-0.72) and LVH-negative patients (5.5% vs. 9.2%; HR, 0.59; 95%CI:
0.44-0.81) compared with non-ARB treatment. The reduction in combined cardiovascular
events (composite of acute myocardial infarction, angina pectoris, and heart failure) due
to valsartan treatment in patients with LVH was significantly larger than that in patients
without LVH (P<0.0001). Changes in blood pressure during the follow-up period did not
differ significantly among the study subgroups.
CONCLUSIONS:

High-risk hypertensive patients with ECG-LVH might gain more cardiovascular benefits
from valsartan add-on treatment, compared with patients without ECG-LVH.
All rights are reserved to the Japanese Circulation Society.

PMID:21436597Free full text

7.

RETRACTED ARTICLE
See: Retraction NoticeHypertens Res. 2011 Jan;34(1):62-9. doi: 10.1038/hr.2010.186. Epub 2010 Oct 7.

Effects of valsartan and amlodipine on cardiorenal protection in
Japanese hypertensive patients: the Valsartan Amlodipine
Randomized Trial.
Narumi H1, Takano H, Shindo S, Fujita M, Mizuma H, Kuwabara Y, Komuro I; Valsartan Amlodipine
Randomized Trial Investigators.

Collaborators (125)Author information
1
Department of Cardiovascular Science and Medicine, Chiba University Graduate
School of Medicine, Chiba, Japan.

Erratum inHypertens Res. 2013 Jul;36(7):655.
Hypertens Res. 2011 Jan;34(1):152.

Retraction in
Retraction: Effects of valsartan and amlodipine on cardiorenal protection in Japanese
hypertensive patients: the Valsartan Amlodipine Randomized Trial. [Hypertens Res. 2017]

Abstract
The Valsartan Amlodipine Randomized Trial, a multicenter, prospective, randomized, openlabeled, blinded-end point trial, was designed to compare the beneficial effects of theangiotensin II receptor blocker valsartan and the calcium channel blocker amlodipine on
cardiovascular events in Japanese essential hypertensive patients. The primary end point
was a composite of all-cause death, sudden death, cerebrovascular death, cardiac events,
vascular events and renal events. The secondary endpoints were effects on left ventricular
hypertrophy, cardiac sympathetic nerve activity and renal function. A total of 1021 patientswere enrolled in the present trial. The mean follow-up period was 3.4 years. There were nosignificant differences in blood pressure (BP) levels between the valsartan group and theamlodipine group throughout the trial. There was no significant difference in the primary
endpoint between the two groups (hazard ratio: 1.0, P = 0.843). No difference in any event
category of the primary endpoint was noted for either group. However, we observed asignificant reduction of left ventricular mass index, as determined by echocardiography, inthe valsartan group compared with the amlodipine group. We also observed a significant
decrease in cardiac sympathetic nerve activity in the valsartan group but not in theamlodipine group. Moreover, there was a significant reduction in the urinary albumin tocreatinine ratio in the valsartan group but not in the amlodipine group. Therefore, although
BP levels were well controlled and remained equal in the two groups, valsartan had more
protective effects on the heart and kidney than amlodipine in Japanese hypertensive
patients.

Comment in
How to evaluate real-world medicine in a Japanese population: important lessons from the
JIKEI, CASE-J, KYOTO and VART studies. [Hypertens Res. 2011]

PMID:20927112

8.

RETRACTED ARTICLE
See: Retraction Notice
J Hypertens. 2010 Jun;28(6):1150-7. doi: 10.1097/HJH.0b013e328338a8b6.

Sex differences in effects of valsartanadministration on
cardiovascular outcomes in hypertensive patients: findings
from the Jikei Heart Study.
Yoshida H1, Shimizu M, Ikewaki K, Taniguchi I, Tada N, Yoshimura M, Rosano G, Dahlöf B, Mochizuki
S; Jikei Heart Study group.

Author information
1
Department of Laboratory Medicine, Jikei University Kashiwa Hospital, Kashiwa,
Chiba, Japan. hyoshida@jikei.ac.jp

Retraction in
Sex differences in effects of valsartan administration on cardiovascular outcomes inhypertensive patients: findings from the Jikei Heart Study: Retraction. [J Hypertens. 2013]

Abstract
OBJECTIVES:

The randomized Jikei Heart Study has demonstrated that the addition of valsartan toconventional treatments prevents more cardiovascular events in Japanese patients withhypertension. This substudy analyses the sex difference in cardiovascular disease risk
reduction in the Jikei Heart Study.
METHODS:

Treatment effects were evaluated by sex (1038 women and 2043 men) as hazard ratioswith 95% confidence intervals (CIs) using Cox regression models adjusted for age, BMI,
smoking, dyslipidemia, diabetes, antihypertensives, and statin use at baseline.
RESULTS:

Women were older, had higher SBP, total and low-density lipoprotein cholesterol but wereless frequently smokers or diabetics, and had a lower DBP and incidence of coronary arterydisease. A greater incidence of primary endpoint, a composite of cardiovascular events,
occurred in men versus women [hazard ratio 1.37 (95% CI 1.02-1.85)]. Men in
the valsartan group had a significant reduction in the primary endpoint [hazard ratio 0.6(95% CI 0.44-0.82), P = 0.001], whereas a nonsignificant effect was found in women[hazard ratio 0.64 (95% CI 0.39-1.06), P = 0.075]. However, statistical heterogeneity ofthis valsartan effect was not found between sexes, and women of at least 55 years of age,mostly after menopause, in the valsartan group showed a significant risk reduction for the
primary endpoint [hazard ratio 0.60 (95% CI 0.36-0.99)].
CONCLUSION:

The valsartan effect was significant in men and in elderly women but consistent in both
sexes. A potential cardiovascular protection by valsartan therapy might be attributed to thecardiovascular risk level but not to the sex difference.

PMID:20467269

9.

RETRACTED ARTICLE
See: Retraction Notice
Eur Heart J. 2009 Oct;30(20):2461-9. doi: 10.1093/eurheartj/ehp363. Epub 2009 Aug 31.

Effects of valsartan on morbidity and mortality in uncontrolled
hypertensive patients with high cardiovascular risks: KYOTO
HEART Study.
Sawada T1, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group.

Author information
1
Department of Cardiovascular Medicine, Kyoto Prefectural University School of
Medicine, Kyoto 602-8566, Japan. tsawada@koto.kpu-m.ac.jp

Retraction in
Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive
patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:24612469, doi: 10.1093/eurheartj/ehp363]. [Eur Heart J. 2013]

Abstract
AIMS:

The objective was to assess the add-on effect of valsartan on top of the conventional
treatment for high-risk hypertension in terms of the morbidity and mortality.
METHODS AND RESULTS:

The KYOTO HEART Study was of a multicentre, Prospective Randomised Open Blinded
Endpoint (PROBE) design, and the primary endpoint was a composite of fatal and non-fatal
cardiovascular events (clintrials.gov NCT00149227). A total of 3031 Japanese patients(43% female, mean 66 years) with uncontrolled hypertension were randomized toeither valsartan add-on or non-ARB treatment. Median follow-up period was 3.27 years. In
both groups, blood pressure at baseline was 157/88 and 133/76 mmHg at the end of study.
Compared with non-ARB arm, valsartan add-on arm had fewer primary endpoints (83 vs.
155; HR 0.55, 95% CI 0.42-0.72, P = 0.00001).
CONCLUSION:

Valsartan add-on treatment to improve blood pressure control prevented morecardiovascular events than conventional non-ARB treatment in high-risk hypertensive
patients in Japan. These benefits cannot be entirely explained by a difference in bloodpressure control.

Comment in
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients withhigh cardiovascular risks: KYOTO HEART Study. [Eur Heart J. 2010]
Angiotensin receptor blockers: baseline therapy in hypertension? [Eur Heart J. 2009]

PMID:19723695

10.

RETRACTED ARTICLE
See: Retraction NoticeHypertens Res. 2008 Jun;31(6):1171-6. doi: 10.1291/hypres.31.1171.

Impact of renin-angiotensin system inhibition on
microalbuminuria in type 2 diabetes: a post hoc analysis of the
Shiga Microalbuminuria Reduction Trial (SMART).
Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A.

Collaborators (32)

Retraction in
Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post
hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). [Hypertens Res.
2014]

Abstract
The Shiga Microalbuminuria Reduction Trial (SMART) showed the advantage of ARB over
CCB beyond the blood pressure (BP)-lowering effect in reducing microalbuminuria. To
further assess the impact of BP control or renin-angiotensin system inhibition on
microalbuminuria, the SMART patients were re-analyzed. Hypertensive patients with type 2diabetes and microalbuminuria were randomly assigned to valsartan or amlodipine
treatment groups for 24 weeks. Target blood pressure was set at <130/80 mmHg. Changes
in the urinary albumin creatinine ratio (ACR) from baseline were assessed in
the valsartan monotherapy (VM) group (n=33), the amlodipine monotherapy (AM) group(n=36), the concomitant valsartan and angiotensin-converting enzyme inhibitor group (VA)
(n=33), and the concomitant amlodipine and angiotensin-converting enzyme inhibitor (AA)group (n=38). At the end of the study, mean BP was not different among the four treatmentgroups. The changes in ACR from baseline to the end of the treatment period in VM, AM,
VA, and AA were -36%, +30%, -26%, and +8%, respectively. The dissociation between theanti-albuminuric and antihypertensive effects of valsartan or amlodipine was observed in
the respective monotherapy groups. In the AA group, however, a significant positive
relationship was found between the changes in ACR and those in systolic BP. In
conclusion, RAS inhibitors may be necessary in order for calcium channel blockers to havean effect on microalbuminuria. Therefore, RAS inhibitors are first-line drugs for
hypertensive patients with type 2 diabetes and microalbuminuria.
TRIAL REGISTRATION:

ClinicalTrials.gov NCT00202618.
PMID:18716365

11.

RETRACTED ARTICLE
See: Retraction Notice
Lancet. 2007 Apr 28;369(9571):1431-1439. doi: 10.1016/S0140-6736(07)60669-2.

Valsartan in a Japanese population with hypertension andother cardiovascular disease (Jikei Heart Study): a randomised,open-label, blinded endpoint morbidity-mortality study.
Mochizuki S1, Dahlöf B2, Shimizu M3, Ikewaki K3, Yoshikawa M3, Taniguchi I3, Ohta M3, Yamada T3, Ogawa
K3, Kanae K3, Kawai M3, Seki S3, Okazaki F3, Taniguchi M3, Yoshida S3, Tajima N4; Jikei Heart Studygroup.

Author information
1

Division of Cardiology, Department of Internal Medicine, Jikei University School of
Medicine, Tokyo, Japan. Electronic address: m_seibu@jikei.ac.jp.
2
Institute of Medicine, Department of Emergency and Cardiovascular Medicine,
Sahlgrenska University Hospital/Östra, Göteborg, Sweden.
3
Division of Cardiology, Department of Internal Medicine, Jikei University School of
Medicine, Tokyo, Japan.
4
Division of Diabetes, Metabolism, and Endocrinology, Department of Internal
Medicine, Jikei University School of Medicine, Tokyo, Japan.

Retraction in
Retraction--Valsartan in a Japanese population with hypertension and other cardiovasculardisease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality
study. [Lancet. 2013]

Abstract
BACKGROUND:

Drugs that inhibit the renin-angiotensin-aldosterone system benefit patients at risk for orwith existing cardiovascular disease. However, evidence for this effect in Asian populations
is scarce. We aimed to investigate whether addition of an angiotensin receptor
blocker, valsartan, to conventional cardiovascular treatment was effective in Japanesepatients with cardiovascular disease.
METHODS:

We initiated a multicentre, prospective, randomised controlled trial of 3081 Japanesepatients, aged 20-79 years, (mean 65 [SD 10] years) who were undergoing conventional
treatment for hypertension, coronary heart disease, heart failure, or a combination of these
disorders. In addition to conventional treatment, patients were assigned either
to valsartan (40-160 mg per day) or to other treatment without angiotensin receptor
blockers. Our primary endpoint was a composite of cardiovascular morbidity and mortality.
Analysis was by intention to treat. The study was registered at clintrials.gov with theidentifier NCT00133328.
FINDINGS:After a median follow-up of 3.1 years (range 1-3.9) the primary endpoint was recorded in
fewer individuals given valsartan than in controls (92 vs 149; absolute risk 21.3 vs 34.5 per1000 patient years; hazard ratio 0.61, 95% CI 0.47-0.79, p=0.0002). This difference wasmainly attributable to fewer incidences of stroke and transient ischaemic attack (29 vs 48;
0.60, 0.38-0.95, p=0.028), angina pectoris (19 vs 53; 0.35, 0.20-0.58, p<0.0001), and heart
failure (19 vs 36; 0.53, 0.31-0.94, p=0.029) in those given valsartan than in the control
group. Mortality or tolerability did not differ between groups.
INTERPRETATION:

The addition of valsartan to conventional treatment prevented more cardiovascular events
than supplementary conventional treatment. These benefits cannot be entirely explained bya difference in blood pressure control.

Comment in
Sum and substance in the Jikei Heart Study. [Lancet. 2007]
Defining the role of angiotensin receptor blocker therapy in Japanese persons with
underlying vascular disease: the Jikei Heart Study. [J Clin Hypertens (Greenwich). 2007]
The JIKEI trial. [Lancet. 2007]
Concerns about the Jikei Heart Study. [Lancet. 2012]

PMID:17467513

12.

RETRACTED ARTICLE
See: Retraction Notice
Diabetes Care. 2007 Jun;30(6):1581-3. Epub 2007 Mar 15.

Reduction of microalbuminuria in patients with type 2 diabetes:
the Shiga Microalbuminuria Reduction Trial (SMART).
Shiga Microalbuminuria Reduction Trial (SMART) Group1, Uzu T, Sawaguchi M, Maegawa H, Kashiwagi
A.

Author information
1
Shiga University of Medical Science, Seta, Otsu, Japan.

Erratum inDiabetes Care. 2013 Dec;36(12):4172.

Retraction in
The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of
microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction
Trial (SMART). Diabetes Care 2007;30:1581-1583. DOI: 10.2337/dc06-2493. Erratum
appears in Diabetes Care 2013;36:4172. DOI: 10.2337/dc13-er12. [Diabetes Care. 2014]

PMID:17363751